Glenmark
A new way for a new world

August 06, 2012

The Manager
Listing Dept,
The National Stock Exchange of India Ltd
Plot No. C/1,G Block
Bandra Kurla Complex
Bandra (E) Mumbai-400051

Dear Sir,

Dear Sir,

We are enclosing herewith a press release informing "**Glenmark Generics receives final ANDA approval for Montelukast Sodium Tablets, 10mg** " for your information and record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.

Sanjay Chowdhary
Jt. Company Secretary &Compliance officer

Tel: 4018 9999 / 4018 9879
Fax No: 4018 9986 (Legal & Secretarial Dept.)

Encl: As above

Glenmark Generics Ltd.

glenmark
A new way for a new world

Press Release

For Immediate Release

Glenmark Generics receives final ANDA approval for Montelukast Sodium Tablets, 10mg

August 6, 2012: Glenmark Generics Inc., USA a subsidiary of Glenmark Generics Limited has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (US FDA) for Montelukast Sodium Tablets, 10mg. Glenmark will commence distribution of the product immediately.

Montelukast Sodium tablets are Glenmark's generic version of Singulair® by Merck & Co., Inc., indicated for the treatment of prophylaxis and chronic treatment of asthma. For the 12 month period ending March 2012, Singulair® garnered annual sales of USD 3.5 billion according to IMS Health.

Glenmark's current portfolio consists of 81 products authorized for distribution in the U.S. marketplace and 39 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

About Glenmark Generics Limited.
Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

#####

For further information, please contact:
Jason D'Souza / Rajdeep Barooah
Glenmark, Mumbai, India Tel: [+91 22] 40189919/984
Email : connect@glenmark-generics.com